1. Engineered self-regulating macrophages for targeted anti-inflammatory drug delivery.
- Author
-
Klimak M, Cimino A, Lenz KL, Springer LE, Collins KH, Harasymowicz NS, Xu N, Pham CTN, and Guilak F
- Subjects
- Animals, Mice, Interleukin 1 Receptor Antagonist Protein genetics, Mice, Inbred C57BL, Arthritis, Experimental drug therapy, Arthritis, Experimental metabolism, Arthritis, Experimental immunology, Arthritis, Experimental genetics, Cells, Cultured, Humans, Macrophages metabolism, Macrophages drug effects, Arthritis, Rheumatoid drug therapy, Arthritis, Rheumatoid metabolism, Arthritis, Rheumatoid genetics, Drug Delivery Systems methods, Anti-Inflammatory Agents pharmacology
- Abstract
Background: Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by increased levels of inflammation that primarily manifests in the joints. Macrophages act as key drivers for the progression of RA, contributing to the perpetuation of chronic inflammation and dysregulation of pro-inflammatory cytokines such as interleukin 1 (IL-1). The goal of this study was to develop a macrophage-based cell therapy for biologic drug delivery in an autoregulated manner., Methods: For proof-of-concept, we developed "smart" macrophages to mitigate the effects of IL-1 by delivering its inhibitor, IL-1 receptor antagonist (IL-1Ra). Bone marrow-derived macrophages were lentivirally transduced with a synthetic gene circuit that uses an NF-κB inducible promoter upstream of either the Il1rn or firefly luciferase transgenes. Two types of joint like cells were utilized to examine therapeutic protection in vitro, miPSCs derived cartilage and isolated primary mouse synovial fibroblasts while the K/BxN mouse model of RA was utilized to examine in vivo therapeutic protection., Results: These engineered macrophages were able to repeatably produce therapeutic levels of IL-1Ra that could successfully mitigate inflammatory activation in co-culture with both tissue-engineered cartilage constructs and synovial fibroblasts. Following injection in vivo, macrophages homed to sites of inflammation and mitigated disease severity in the K/BxN mouse model of RA., Conclusion: These findings demonstrate the successful development of engineered macrophages that possess the ability for controlled, autoregulated production of IL-1 based on inflammatory signaling such as via the NF-κB pathway to mitigate the effects of this cytokine for applications in RA or other inflammatory diseases. This system provides proof of concept for applications in other immune cell types as self-regulating delivery systems for therapeutic applications in a range of diseases., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF